As president and director of Fred Hutch, Dr. Gilliland sets the strategic direction of the center, oversees center-wide initiatives and represents the Hutch’s interests to major partners and governmental bodies. Dr. Gilliland’s background is as a researcher and clinician specializing in blood cancers like leukemia and myelodysplastic syndrome. He has made major contributions to the understanding of the genetic basis of blood diseases, particularly leukemia. Prior to coming to Fred Hutch in 2015, Dr. Gilliland held numerous clinical, research and leadership titles, including professor at Harvard Medical School, director of the leukemia program at the Dana-Farber/Harvard Cancer Center, senior vice president and global oncology franchise head at Merck and Co., and vice dean of the Perelman School of Medicine at the University of Pennsylvania.
Dr. Gilliland earned a Ph.D. in microbiology from the University of California, Los Angeles, in 1980 and a medical degree from the University of California, San Francisco, in 1984. He has received many awards and honors in his career, including the William Dameshek Prize from the American Society of Hematology, the Emil J. Freireich Award from the MD Anderson Cancer Center and the Stanley J. Korsmeyer Award from the American Society for Clinical Investigation, of which he is an elected member. He is also an elected member of the Association of American Physicians.